Kidney cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• YAP 0
• HIF-1 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

24 of 56+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finland· EU contribution €226,277· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €1,500,000· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €2,496,625· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, France· EU contribution €5,577,694· until Apr 2028· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €5,906,596· until Mar 2027· 7 countries

5 of 6 running projects, newest first. Listed amounts together: €19.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Updated 20 Oct 2026

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

  NCT04902040· M.D. Anderson Cancer Center· Updated 30 Apr 2026

  “PI requested.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

  NCT03829501· Kymab Limited· Updated 2 Apr 2025

  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

  NCT03024437· Roberto Pili· Updated 20 Mar 2025

  “Genentech has closed the study due to lack of data with Atezo”Registry text, quoted unchanged. Source

• Terminated

  Study of INCB086550 in Select Solid Tumors

  NCT04629339· Incyte Corporation· Updated 13 Mar 2025

  “Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.”Registry text, quoted unchanged. Source

• Terminated

  Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

  NCT03809624· Inhibrx Biosciences, Inc· Updated 23 Oct 2024

  “Program terminated due to lack of meaningful efficacy signal.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Merck Sharp & Dohme LLC· Source

• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

  NCT04704219· Merck Sharp & Dohme LLC· Source

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Arcus Biosciences, Inc.· Source

• A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

  NCT05468697· Merck Sharp & Dohme LLC· Source

• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Source

• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Merck Sharp & Dohme LLC· Source

• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

  NCT05899049· Merck Sharp & Dohme LLC· Source

• A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

  NCT06307431· Merck Sharp & Dohme LLC· Source

• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

  NCT05239728· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors.

  Cell Stress Chaperones, Nov 2025

• Epigallocatechin-3-gallate Sensitizes Human 786-O Renal Cell Carcinoma Cells to TRAIL-Induced Apoptosis.

  Cell Biochem Biophys, May 2015

• Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.

  Int J Clin Exp Pathol, Mar 2015

• Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.

  PLoS One, Apr 2014

• Dietary selenium supplementation modifies breast tumor growth and metastasis.

  Int J Cancer, Jul 2013

• Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.

  Urol Oncol, Jun 2011

• Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA.

  J Pineal Res, Jan 2011

• Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.

  Int J Oncol, Dec 2010

• A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells.

  Int J Oncol, Dec 2009

• EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression.

  Oncol Rep, Mar 2009

See which targets of this disease your abstract mentions, and go to the people working on them.